June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
αB-crystallin super chaperone for treating protein aggregation diseases
Author Affiliations & Notes
  • SUNDARARAJAN MAHALINGAM
    Department of Ophthalmology, University of Missouri, Columbia, Missouri, United States
  • Swati Srivastava
    Department of Ophthalmology, University of Missouri, Columbia, Missouri, United States
  • Puttur Santhoshkumar
    Department of Ophthalmology, University of Missouri, Columbia, Missouri, United States
  • K Krishna Sharma
    Department of Ophthalmology, University of Missouri, Columbia, Missouri, United States
    Department of Biochemistry, University of Missouri, Columbia, Missouri, United States
  • Footnotes
    Commercial Relationships   SUNDARARAJAN MAHALINGAM, None; Swati Srivastava, None; Puttur Santhoshkumar, None; K Krishna Sharma, None
  • Footnotes
    Support  NIH Grant EY023219
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2061. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SUNDARARAJAN MAHALINGAM, Swati Srivastava, Puttur Santhoshkumar, K Krishna Sharma; αB-crystallin super chaperone for treating protein aggregation diseases. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2061.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : αB-crystallin super chaperone (αBΔ54-61) can be prepared by deleting 54-61 amino acid residues in αB-crystallin. The objective of this study was to evaluate the therapeutic potentials of αBΔ54-61 super chaperone using cell culture systems and C. elegans model system. Additionally, whether heat- or urea-induced unfolding and refolding of αBΔ54-61 and WT protein increases the proteins ability to protect cells from oxidative stress and apoptosis was also evaluated.

Methods : The therapeutic efficacy of the WT- and Δ54-61-αB-crystallins was investigated a C. elegans model (CL4176) for Alzheimer's disease (AD). The αB-crystallin response to counter thermal and chemical-induced stress was studied using wild type (N2 strain) C. elegans. The chaperone-like activity of heat-/urea-activated wild-type and αBΔ54-61 were measured using luciferase and lysozyme as client proteins. The structural and molecular changes in Δ54-61-αB-crystallin after urea/heat activation were investigated using multi-angle light scattering analysis method. The cytoprotective effects of the native and heat/urea-activated αB-crystallins were evaluated in ARPE-19 cells using cell integrity assay and 2,7-dichlorofluorescin diacetate staining.

Results : The super chaperone protected C. elegans (N2 strain) from paraquat and juglone-induced oxidative stress to a greater extent than did by wild-type αB-crystallin. The mutant super chaperone also prevented Aβ-induced toxicity on ARPE-19 cells in a more effective manner when compared to the wild-type protein. The mutant αB-crystallin also delayed Aβ-induced paralysis in a C. elegans model for AD and showed 10% increase in lifespan of the worm. C. elegans pre-treated with mutant αB-crystallin and exposed to thermal stress (35°C) showed a 11% increase in survival. In contrast, the wild-type protein treated worms showed no significant increase in survival when compared to placebo. Heat- and urea-induced unfolding/refolding events showed two-fold increase in the chaperone-like function with a concomitant increase in surface hydrophobicity of the mutant protein, even though increased hydrophobicity didn’t result in enhanced cytoprotective effects.

Conclusions : Our findings suggest that αB-crystallin super chaperone (αBΔ54-61) has improved therapeutic potential in cell culture and C. elegans model system.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×